Mid-November 2025
Andrew J. Cowan, MD
Dr. Cowan shares his tips for taking full advantage of the offerings at large conferences like the ASH Annual Meeting.
Mid-November 2025
Using patient-reported outcome instruments to evaluate health-related quality of life in tandem with clinician-reported adverse events is beneficial in evaluating the efficacy and tolerability of treatments such as polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).
Mid-November 2025
At the 67th American Society of Hematology Annual Meeting and Exposition, the Education Spotlight Session, “The Changing Face of Chronic Myelogenous Leukemia,” will tackle the changing needs for adult and pediatric patients with chronic myelogenous leukemia (CML).
Mid-November 2025
Researchers revealed that ongoing cytopenias beyond day 100 after B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell delivery are linked to shorter progression-free survival and overall survival in patients with multiple myeloma (MM).
